Advertisement
Advertisement

TXG

TXG logo

10x Genomics, Inc. Class A Common Stock

39.61
USD
Sponsored
+1.27
+3.30%
Jul 01, 11:54 UTC -4
Open

TXG Earnings Reports

Positive Surprise Ratio

TXG beat 15 of 27 last estimates.

56%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$148.00M
/
-$0.24
Implied change from Q1 26 (Revenue/ EPS)
-1.89%
/
+140.00%
Implied change from Q2 25 (Revenue/ EPS)
-14.41%
/
-185.71%

10x Genomics, Inc. Class A Common Stock earnings per share and revenue

On May 07, 2026, TXG reported earnings of -0.10 USD per share (EPS) for Q1 26, beating the estimate of -0.29 USD, resulting in a 66.04% surprise. Revenue reached 150.84 million, compared to an expected 147.82 million, with a 2.05% difference. The market reacted with a -3.66% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 16 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 148.00 million USD, implying an increase of 140.00% EPS, and decrease of -1.89% in Revenue from the last quarter.
FAQ
For Q1 2026, 10x Genomics, Inc. Class A Common Stock reported EPS of -$0.10, beating estimates by 66.04%, and revenue of $150.84M, 2.05% above expectations.
The stock price moved down -3.66%, changed from $22.42 before the earnings release to $21.60 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 16 analysts, 10x Genomics, Inc. Class A Common Stock is expected to report EPS of -$0.24 and revenue of $148.00M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement